Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer

REGULATORY

Lund, Sweden, April 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that preclinical data on the CTLA-4 x OX40 bispecific antibody ATOR-1015 is published in the Journal for ImmunoTherapy of Cancer.

The published data show that ATOR-1015 localizes to the tumor with anti-tumor effects in several experimental tumor models, including bladder, colon and pancreas cancer. Furthermore, the data demonstrate that ATOR-1015 induces a tumor-specific and long-term immunological memory and an enhanced anti-tumor response in combination with PD-1 blocking therapy.

The data support the ongoing clinical development of ATOR-1015, currently evaluated in a first-in-human Phase I study (NCT03782467). The results of this study are expected to read out in the second half of 2020.

Title: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.

Journal: Journal for ImmunoTherapy of Cancer (https://doi.org/10.1186/s40425-019-0570-8)

Authors: Anne Månsson-Kvarnhammar et al.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications

Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com

The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CEST on April 11, 2019.

About ATOR-1015
ATOR-1015 is tumor-localizing CTLA-4 bispecific antibody with augmented depletion of regulatory T cells. It is wholly-owned by Alligator. ATOR-1015 binds to two different immune receptors: the checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40. The immune activation is increased in areas where both target molecules are expressed at high levels, notably in the tumor microenvironment, which is believed to reduce adverse immune reactions.

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit http://www.alligatorbioscience.com.

ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

Download as PDF